SI1755642T1 - Aneksin V za preprečevanje rupture plaka - Google Patents

Aneksin V za preprečevanje rupture plaka

Info

Publication number
SI1755642T1
SI1755642T1 SI200530951T SI200530951T SI1755642T1 SI 1755642 T1 SI1755642 T1 SI 1755642T1 SI 200530951 T SI200530951 T SI 200530951T SI 200530951 T SI200530951 T SI 200530951T SI 1755642 T1 SI1755642 T1 SI 1755642T1
Authority
SI
Slovenia
Prior art keywords
annexin
binding
immunoglobulins
atherosclerosis
atherothrombosis
Prior art date
Application number
SI200530951T
Other languages
English (en)
Inventor
Anna Frostegard
Johan Frostegard
Original Assignee
Athera Biotechnologies Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Athera Biotechnologies Ab filed Critical Athera Biotechnologies Ab
Publication of SI1755642T1 publication Critical patent/SI1755642T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Escalators And Moving Walkways (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
SI200530951T 2004-04-15 2005-04-15 Aneksin V za preprečevanje rupture plaka SI1755642T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52138504P 2004-04-15 2004-04-15
EP05735990A EP1755642B1 (en) 2004-04-15 2005-04-15 Annexin v for preventing plaque rupture

Publications (1)

Publication Number Publication Date
SI1755642T1 true SI1755642T1 (sl) 2010-05-31

Family

ID=34966761

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200530951T SI1755642T1 (sl) 2004-04-15 2005-04-15 Aneksin V za preprečevanje rupture plaka

Country Status (15)

Country Link
US (1) US20080044404A1 (sl)
EP (1) EP1755642B1 (sl)
JP (2) JP2007532617A (sl)
CN (1) CN1997385B (sl)
AT (1) ATE454898T1 (sl)
AU (1) AU2005232436C1 (sl)
CA (1) CA2563408C (sl)
CY (1) CY1109959T1 (sl)
DE (1) DE602005018914D1 (sl)
DK (1) DK1755642T3 (sl)
ES (1) ES2356364T3 (sl)
PL (1) PL1755642T3 (sl)
PT (1) PT1755642E (sl)
SI (1) SI1755642T1 (sl)
WO (1) WO2005099744A1 (sl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7645739B2 (en) 2001-02-21 2010-01-12 Alavita Pharmaceuticals, Inc. Modified annexin compositions and methods of using same
PL2234631T3 (pl) 2007-12-18 2013-03-29 Athera Biotechnologies Ab Związki i metody stosowane w terapii choroby naczyniowej
ES2630013T3 (es) * 2008-02-22 2017-08-17 Annexin Pharmaceuticals Ab Compuestos y procedimientos para la prevención o tratamiento de reestenosis
EP2350112A4 (en) 2008-10-03 2013-01-16 Advanced Proteome Therapeutics Inc Site specific N-termin protein modifications and conjugate formation
JP5590621B2 (ja) 2008-10-17 2014-09-17 ロンドン ヘルス サイエンシーズ センター リサーチ インコーポレイテッド 炎症性障害の処置を処置するためのアネキシンおよびその使用
EP2380023A2 (en) * 2008-12-19 2011-10-26 Medirista Biotechnologies AB Oxidized cardiolipin as a novel pro-inflammatory factor
WO2011160845A2 (en) 2010-06-24 2011-12-29 Medirista Biotechnologies Ab Oxidized phospholipids and lipoproteins, and antibodies thereto, as biomarkers of inflammatory conditions and methods of treatment
CN102690345B (zh) * 2011-03-24 2014-03-19 江苏靶标生物医药研究所有限公司 人膜联蛋白v变体及其表达、制备和应用
PL2694538T3 (pl) 2011-04-05 2017-04-28 Annexin Pharmaceuticals Ab Sposoby terapeutyczne i profilaktyczne, zastosowania i kompozycje zawierające aneksynę a5
WO2013109144A1 (en) * 2012-01-18 2013-07-25 Stichting Katholieke Universiteit Annexin a5 snp in atherosclerosis
GB2542391A (en) 2015-09-17 2017-03-22 Annexin Pharmaceuticals Ab Process of manufacture
GB2552724B (en) * 2015-09-17 2020-05-06 Annexin Pharmaceuticals Ab Purification of Annexin A5 by anion exchange and affinity chromatography
GB2552853B (en) * 2015-09-17 2018-11-21 Annexin Pharmaceuticals Ab Purification of Annexin A5 from a composition that includes a calcium ion chelator
CN105327042A (zh) * 2015-12-16 2016-02-17 刘爱玲 一种治疗颈动脉斑块的中药药膏及制备方法
GB201702144D0 (en) 2017-02-09 2017-03-29 Annexin Pharmaceuticals Ab Therapeutic compositions
CN108159421B (zh) * 2018-02-05 2021-05-18 苏州大学 磷脂酰丝氨酸阻断剂在制备治疗血小板数量减少相关疾病药物中的用途
TW202146042A (zh) * 2020-03-06 2021-12-16 瑞典商阿斯特捷利康公司 用於治療動脈和靜脈血栓形成的協同且靶向的組成物
WO2022263407A2 (en) 2021-06-14 2022-12-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Mutated annexin a5 polypeptides and uses thereof for therapeutic purposes
WO2023143463A1 (en) * 2022-01-30 2023-08-03 Nanjing Reju Therapeutics , Inc. Fusion protein and application thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5632986A (en) * 1991-05-09 1997-05-27 The University Of Washington Phospholipid-targeted thrombolytic agents
US5968477A (en) * 1994-01-24 1999-10-19 Neorx Corporation Radiolabeled annexin conjugates with hexose and a chelator
EP0741144B1 (en) * 1994-11-11 2002-07-24 Noboru Kaneko Antiannexin-v monoclonal antibody, process for producing the same, and use therof
US6284475B1 (en) * 1997-07-11 2001-09-04 Mount Sinai School Of Medicine Of The City Of New York Assays for diagnosis of thrombophilic disease
US5932712A (en) * 1997-07-31 1999-08-03 Incyte Pharmaceuticals, Inc. Annexin binding protein
US6228360B1 (en) * 1998-08-19 2001-05-08 Ajinomoto Co., Inc. Antithrombotic agent and humanized anti-von Willebrand factor monoclonal antibody
CA2382676A1 (en) * 1999-11-05 2001-05-17 Warner-Lambert Company Prevention of plaque rupture by acat inhibitors
CA2400504A1 (en) * 2000-03-10 2001-09-13 Egil Lien Composition for the treatment of heart failure
GB0005867D0 (en) * 2000-03-10 2000-05-03 Medinnova Sf Method
EP1278540B1 (en) * 2000-05-05 2008-05-14 Laboratoires Serono SA Use of il-18 inhibitors for the treatment and/or prevention of atherosclerosis
IL135993A0 (en) * 2000-05-05 2001-05-20 Omrix Biopharmaceuticals Pharmaceutical composition for the treatment of fibrosis
EP1839670A3 (en) * 2001-02-21 2009-11-11 Alavita Pharmaceuticals, Inc. Modified Annexin Proteins and their use against thrombosis
US20050013778A1 (en) * 2001-04-03 2005-01-20 Theseus Imaging Corporation Methods and compositions for predicting the response to a therapeutic regimen in a subject having a disease associated with cell death
US20040203083A1 (en) * 2001-04-13 2004-10-14 Biosite, Inc. Use of thrombus precursor protein and monocyte chemoattractant protein as diagnostic and prognostic indicators in vascular diseases
EP1666881B1 (en) * 2001-05-04 2010-02-17 Biosite Incorporated Diagnostic markers of acute coronary syndromes and methods of use thereof
US20030152513A1 (en) * 2001-09-06 2003-08-14 Imetrix, Inc. Intravascular delivery of therapeutic and imaging agents to stressed and apoptotic cells using annexin V as a targeting vector
US20040042959A1 (en) * 2002-08-28 2004-03-04 Michael Montalto Imaging cell death in vivo using non-radionuclide contrast agents

Also Published As

Publication number Publication date
JP2012136536A (ja) 2012-07-19
WO2005099744A1 (en) 2005-10-27
DK1755642T3 (da) 2010-05-10
PL1755642T3 (pl) 2010-06-30
US20080044404A1 (en) 2008-02-21
ATE454898T1 (de) 2010-01-15
CA2563408A1 (en) 2005-10-27
EP1755642A1 (en) 2007-02-28
CN1997385B (zh) 2012-01-11
EP1755642B1 (en) 2010-01-13
ES2356364T3 (es) 2011-04-07
JP2007532617A (ja) 2007-11-15
AU2005232436B2 (en) 2010-03-11
CY1109959T1 (el) 2014-09-10
CA2563408C (en) 2015-08-25
AU2005232436A1 (en) 2005-10-27
CN1997385A (zh) 2007-07-11
DE602005018914D1 (de) 2010-03-04
AU2005232436C1 (en) 2010-08-26
PT1755642E (pt) 2010-04-20

Similar Documents

Publication Publication Date Title
SI1755642T1 (sl) Aneksin V za preprečevanje rupture plaka
PH12015500576A1 (en) Anti-notch3 agonist antibodies and their use in the treatment of notch3-related diseases
MY150602A (en) Subtituted-quinoxaline-type piperidine compounds and the uses thereof
MX2007003078A (es) Compuestos de imidazoquinolina.
WO2007075439A3 (en) Compositions and methods for treating obesity and related metabolic disorders
IN2012DN02589A (sl)
MX2009000285A (es) Piperidinas sustituidas que incrementan la actividad de p53 y usos de las mismas.
WO2004013172A3 (en) Fragments of beta-amyloid as targets for vaccination against alzheimer disease
HK1133787A1 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2007138466A3 (en) Pharmaceutical compositions comprising meloxicam and tramadol combination
MY153948A (en) Substituted-quinoxaline-type bridged-piperidine compounds and the uses thereof
MY156275A (en) Compositions comprising tramadol and celecoxib in the treatment of pain
CR11692A (es) USO DE VARIANTES DE IGF-I PEGiladas PARA EL TRATAMIENTO DE TRASTORNOS NEUROMUSCULARES
WO2007146983A3 (en) Compositions comprising tegaserod alone or in combination with a proton pump inhibitor for treating or preventing gastric injury
TW200730190A (en) New combination to treat liver fibrosis
PL1622939T3 (pl) Aktywne warianty białka wiążącego IL-18 i ich medyczne zastosowania
WO2011011706A3 (en) Methods and compositions for treating or preventing autoimmune diseases using immunomodulatory agents
WO2009140265A3 (en) Methods and compositions for the treatment of obesity
WO2005123113A3 (en) Interferon compositions and methods of use thereof
HK1137765A1 (sl)
NZ702645A (en) A method of improving liver function
WO2006103118A3 (en) Therapeutic use of scin, a staphylococcal complement inhibitor in inflammatory diseases
MX2007010322A (es) Extractos de planta y metodos y usos de los mismos.
WO2006023882A3 (en) Anti-perspirant compositions with improved properties
TW200603791A (en) Compounds and compositions as cathepsin S inhibitors